Advertisement
Advertisement
U.S. markets open in 2 hours 5 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Silo Pharma, Inc. (SILO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.6300-0.1000 (-3.66%)
At close: 04:00PM EST
2.4800 -0.15 (-5.70%)
Pre-Market: 07:23AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close2.7300
Open2.6300
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range2.4563 - 2.6600
52 Week Range0.1700 - 12.4500
Volume209,058
Avg. Volume458,114
Market Cap8.255M
Beta (5Y Monthly)-0.76
PE Ratio (TTM)0.80
EPS (TTM)3.2700
Earnings DateNov 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SILO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Silo Pharma, Inc.
    WPM: Raising target price to $37.00WHEATON PRECIOUS METALS CORP has an Investment Rating of SELL; a target price of $37.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Silo Pharma Announces Stock Repurchase Program

    ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1,000,000 of the Company's common stock. The Company may purchase common stock in the open market, through privately negotiated transactions, or otherwise, in compliance w

  • GlobeNewswire

    Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

    Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS, NJ, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a progress update on its sponsored research study with the University of California, San Francisco

  • GlobeNewswire

    Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

    SPU-21 effective in controlling arthritis progression. SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous a

Advertisement
Advertisement